CN113521069A - 用于治疗癌症的mdm2抑制剂的给药方案 - Google Patents

用于治疗癌症的mdm2抑制剂的给药方案 Download PDF

Info

Publication number
CN113521069A
CN113521069A CN202110980773.0A CN202110980773A CN113521069A CN 113521069 A CN113521069 A CN 113521069A CN 202110980773 A CN202110980773 A CN 202110980773A CN 113521069 A CN113521069 A CN 113521069A
Authority
CN
China
Prior art keywords
days
compound
salt
pharmaceutical composition
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110980773.0A
Other languages
English (en)
Chinese (zh)
Inventor
席奈奇亚契
蔡胜力
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of CN113521069A publication Critical patent/CN113521069A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202110980773.0A 2015-10-23 2016-10-21 用于治疗癌症的mdm2抑制剂的给药方案 Pending CN113521069A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562245632P 2015-10-23 2015-10-23
US62/245632 2015-10-23
CN201680061650.4A CN108135892A (zh) 2015-10-23 2016-10-21 用于治疗癌症的mdm2抑制剂的给药方案

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680061650.4A Division CN108135892A (zh) 2015-10-23 2016-10-21 用于治疗癌症的mdm2抑制剂的给药方案

Publications (1)

Publication Number Publication Date
CN113521069A true CN113521069A (zh) 2021-10-22

Family

ID=57349101

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202110980773.0A Pending CN113521069A (zh) 2015-10-23 2016-10-21 用于治疗癌症的mdm2抑制剂的给药方案
CN201680061650.4A Pending CN108135892A (zh) 2015-10-23 2016-10-21 用于治疗癌症的mdm2抑制剂的给药方案

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201680061650.4A Pending CN108135892A (zh) 2015-10-23 2016-10-21 用于治疗癌症的mdm2抑制剂的给药方案

Country Status (8)

Country Link
US (3) US20180296547A1 (enExample)
EP (1) EP3364972A1 (enExample)
JP (4) JP6855472B2 (enExample)
KR (1) KR20180064540A (enExample)
CN (2) CN113521069A (enExample)
HK (1) HK1253098A1 (enExample)
TW (3) TWI806822B (enExample)
WO (1) WO2017069289A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI697329B (zh) * 2015-04-13 2020-07-01 日商第一三共股份有限公司 血液癌症治療用之醫藥及其用途
HK1253098A1 (zh) * 2015-10-23 2019-06-06 Daiichi Sankyo Company, Limited 用於治疗癌症的mdm2抑制剂的给药方案
US10409015B1 (en) 2015-12-15 2019-09-10 Optomind Inc. Optical receiving device including focusing lens and reflector mounted to housing body and collimating lens mounted to housing cover
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
WO2023016977A1 (en) * 2021-08-09 2023-02-16 Boehringer Ingelheim International Gmbh Oral composition comprising a mdm2-antagonist for cancer therapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140336202A1 (en) * 2011-12-07 2014-11-13 Duke University Methods of identifying and using mdm2 inhibitors
WO2015033974A1 (ja) * 2013-09-04 2015-03-12 第一三共株式会社 スピロオキシインドール誘導体の製造方法
CN104812757A (zh) * 2012-09-06 2015-07-29 第一三共株式会社 二螺吡咯烷衍生物的晶体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE470665T1 (de) * 2006-03-22 2010-06-15 Janssen Pharmaceutica Nv Cycloalkylaminderivate als inhibitoren der wechselwirkung zwischen mdm2 und p53
EP2059236A2 (en) * 2006-08-21 2009-05-20 Synta Pharmaceuticals Corporation Combination with bis(thiohydrazide amides) for treating cancer
JP5438008B2 (ja) * 2007-09-21 2014-03-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ＭＤＭ２とｐ５３の間の相互作用の阻害剤
TR201807311T4 (tr) * 2011-03-10 2018-06-21 Daiichi Sankyo Co Ltd Dispiropirolidin derivesi.
JP5958208B2 (ja) * 2012-09-10 2016-07-27 凸版印刷株式会社 包装袋
EP3094746A1 (en) * 2014-01-14 2016-11-23 Daiichi Sankyo Company, Limited Gene signatures associated with sensitivity to mdm2 inhibitors
CN107427501B (zh) * 2015-02-20 2023-12-01 第一三共株式会社 通过联合使用治疗癌症的方法
TWI697329B (zh) * 2015-04-13 2020-07-01 日商第一三共股份有限公司 血液癌症治療用之醫藥及其用途
HK1253098A1 (zh) * 2015-10-23 2019-06-06 Daiichi Sankyo Company, Limited 用於治疗癌症的mdm2抑制剂的给药方案

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140336202A1 (en) * 2011-12-07 2014-11-13 Duke University Methods of identifying and using mdm2 inhibitors
CN104812757A (zh) * 2012-09-06 2015-07-29 第一三共株式会社 二螺吡咯烷衍生物的晶体
WO2015033974A1 (ja) * 2013-09-04 2015-03-12 第一三共株式会社 スピロオキシインドール誘導体の製造方法

Also Published As

Publication number Publication date
JP2024164122A (ja) 2024-11-26
TW201722427A (zh) 2017-07-01
JP6855472B2 (ja) 2021-04-07
WO2017069289A1 (en) 2017-04-27
KR20180064540A (ko) 2018-06-14
US20180296547A1 (en) 2018-10-18
US20220071975A1 (en) 2022-03-10
TWI806822B (zh) 2023-07-01
JP7192011B2 (ja) 2022-12-19
HK1253098A1 (zh) 2019-06-06
US11058673B2 (en) 2021-07-13
CN108135892A (zh) 2018-06-08
TW202332444A (zh) 2023-08-16
EP3364972A1 (en) 2018-08-29
TW202515561A (zh) 2025-04-16
JP2021098750A (ja) 2021-07-01
US20190201386A1 (en) 2019-07-04
JP2023025214A (ja) 2023-02-21
JP2018531273A (ja) 2018-10-25

Similar Documents

Publication Publication Date Title
Fu et al. Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
JP7192011B2 (ja) がんを治療するためのｍｄｍ２阻害剤の投与計画
AU2016287508B2 (en) Methods of treating solid tumors using nanoparticle MTOR inhibitor combination therapy
US20210093730A1 (en) Biomarkers for antibody-drug conjugate monotherapy or combination therapy
HK1221408A1 (zh) 用於治疗成胶质细胞瘤的组合疗法
JP2018531273A6 (ja) がんを治療するためのｍｄｍ２阻害剤の投与計画
EP3600410A1 (en) Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer
WO2023056431A1 (en) Methods of treating solid tumor using heteroaromatic macrocyclic ether compounds
AU2025202230A1 (en) Biomarkers for sacituzumab govitecan therapy
US20240197730A1 (en) Cancer treatment using parp inhibitors and plk1 inhibitors
US20230172935A1 (en) Methods of monitoring kras mutations
EP3836932A2 (en) Method for treating pancreatic cancer
US20240165112A1 (en) Therapy for the treatment of cancer
WO2025080769A1 (en) Methods of treating cancer
WO2020205627A1 (en) Use of biomarker in cancer therapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20211022

WD01 Invention patent application deemed withdrawn after publication